News

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

GE HealthCare

The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.” 

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.

Boston Scientific ACURATE neo2 aortic valve system self-expanding TAVR valve

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Hexoskin Medical System

According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials. 

 Emily Sedgwick, MD, MBA

The breast screening provider has picked Emily Sedgwick, MD, MBA, to fill the key role and is opening new centers in Texas and Colorado. 

allstate

Filed in a Texas federal court, the complaint names Prime Imaging Partners and Memorial MRI & Diagnostic among numerous defendants, with the alleged auto-injury scheme occurring from 2019-2023. 

piedmont

The private equity-backed, Tennessee-based imaging group is expanding in Georgia and Missouri through partnerships with Piedmont and BJC HealthCare, respectively. 

Redo TAVR: A 26-mm Sapien 3 device (Edwards Lifesciences) implanted within a 29-mm CoreValve device (Medtronic). Image courtesy of EuroIntervention.

Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves.

heart drugs with stethoscope

The popular DOAC was linked to more bleeding events than warfarin, but fewer reports of intracardiac thrombi and other adverse outcomes. Researchers presented their findings at the AHA's Scientific Sessions 2024 conference in Chicago.

Donald J. Trump 2024

In this RB opinion piece, Radiology Business Management Association leaders discuss what President-elect Trump's 2nd term might mean for the specialty. 

question mark conundrum uncertainty

Harvard researchers recently set out to answer this question, sharing their results Friday in the Journal of the American College of Radiology 

Around the web

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.” 

A clinical trial focused on patients with HFpEF is expected to be completed by July 2026.